GRIK3
Glutamate receptor ionotropic, kainate 3
As of the edition of 20 October 2026, GRIK3 (glutamate receptor ionotropic, kainate 3, UniProt Q13003) has 3 drugs tested at it and 7 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13003
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Nervous system; Mental health; Nutrition and metabolism; Chemically induced; Hormones; Heart and blood vessels; Inherited and neonatal; Immune system
- Registered trials of its drugs
- 227
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Topiramate | Marketed | Phase 4 | none listed |
| Selurampanel | Stopped | Phase 2 | none listed |
| Tezampanel anhydrous | Active | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 7 |
| Total on the list | 7 |